Engineered bispecific antibodies achieve broad and potent protection against multiple ebolavirus species

Ebolaviruses, including EBOV, SUDV, and BDBV, cause severe hemorrhagic fever, yet currently licensed monoclonal antibody (mAb) therapies against EBOV lack cross-species efficacy. While mAbs offer high specificity, favourable safety profiles, and durable serum persistence, their susceptibility to vir...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jinge Zhou, Baoyue Zhang, Yanfeng Yao, Fangxu Li, Shaohong Chen, Yan Wu, Ying Xie, Xiaoping Guo, Wujian Li, Cheng Peng, Yun Peng, Ge Gao, Feihu Yan, Rui Gong, Xinghai Zhang, Sandra Chiu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2026-12-01
coleção:	Emerging Microbes and Infections
Assuntos:	Ebolavirus broadly neutralizing antibodies bispecific antibody engineering In vivo potection viral escape
Acesso em linha:	https://www.tandfonline.com/doi/10.1080/22221751.2026.2668755
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!